**Name of journal: World Journal of Radiology**

**ESPS Manuscript NO: 7967**

**Columns: review**

**Partial splenic artery embolization in cirrhotic patients**

Hadduck TA *et al*. Partial splenic artery embolization in cirrhosis

Tyson A Hadduck, Justin P McWilliams

**Tyson A Hadduck, Justin P McWilliams,** Department of Interventional Radiology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, United States

**Author contributions:** Hadduck TA and McWilliams JP equally contributed to this paper.

**Correspondence to: Justin McWilliams, MD, Assistant Professor,** Department of Interventional Radiology, David Geffen School of Medicine, UCLA, 757 Westwood Plaza, Suite 2125C, Los Angeles, CA 90095, United States. jumcwilliams@mednet.ucla.edu

**Telephone:** +1-310-2678773 **Fax:** +1-310-2673631

**Received:** December 9, 2013 **Revised:** February 9, 2014

**Accepted:** May 8, 2014

**Published online:**

**Abstract**

Splenomegaly is a common sequela of cirrhosis, and is frequently associated with decreased hematologic indices including thrombocytopenia and leukopenia. Partial splenic artery embolization (PSE) has been demonstrated to effectively increase hematologic indices in cirrhotic patients with splenomegaly. This is particularly valuable amongst those cirrhotic patients who are not viable candidates for splenectomy. Although PSE was originally developed decades ago, it has recently received increased attention. Presently, PSE is being utilized to address a number of clinical concerns in the setting of cirrhosis, including: decreased hematologic indices, portal hypertension and its associated sequela, and splenic artery steal syndrome. Following PSE patients demonstrate significant increases in platelets and leukocytes. Though progressive decline of hematologic indices occur following PSE, they remain improved as compared to pre-procedural values over long-term follow-up. PSE, however, is not without risk and complications of the procedure may occur. The most common complication of PSE is post-embolization syndrome, which involves a constellation of symptoms including fever, pain, and nausea/vomiting. The rate of complications has been shown to increase as the percent of total splenic volume embolized increases. The purpose of this review is to explore the current literature in regards to PSE in cirrhotic patients and to highlight their techniques, and statistically summarize their results and associated complications.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Partial splenic embolization; Cirrhosis; Liver disease; Thrombocytopenia; Leukopenia

**Core tip:** Splenomegaly is a common sequela of cirrhosis, and is frequently associated with decreased hematologic indices including thrombocytopenia and leukopenia. Partial splenic artery embolization (PSE) has been demonstrated to effectively increase hematologic indices in cirrhotic patients with splenomegaly. This is particularly valuable amongst cirrhotic patients that are not viable candidates for splenectomy. Although PSE was originally developed decades ago, it has recently received increased attention. Presently, PSE is being utilized to address a number of clinical concerns in the setting of cirrhosis, including: decreased hematologic indices, portal hypertension and its associated sequela, and splenic artery steal syndrome.

Hadduck TA, McWilliams JP. Partial splenic artery embolization in cirrhotic patients. *World J of Radiol* 2014; In Press

**INTRODUCTION**

Portal hypertension in the setting of cirrhosis commonly leads to splenomegaly[1]. Additionally, cirrhosis is frequently associated with decreased hematologic indices, including thrombocytopenia and anemia. The prevalence of leukopenia amongst cirrhotic patients is more common than in the general population, and varies from 5% to 61%[2]. The pathogenesis of each hematologic deficiency in cirrhotic patients is multi-factorial in nature. Splenic sequestration, however, serves as a common link; and is a contributing factor in the development of thrombocytopenia, anemia, and leukopenia in cirrhotic patients[3].

Decreased hematologic indices can have significant clinical ramifications. Thrombocytopenia increases a patient’s risk of spontaneous bleeding, and may preclude surgical or endovascular interventions. Leukopenia decreases the patient’s ability to overcome infection, and may serve as a contraindication to the use of chemotherapies in hepatocellular carcinoma. Anemia places a patient at increased risk should bleeding occur, may prevent surgical or endovascular interventions and can leave a patient dependent on transfusions[2].

Operative splenectomy can be used to treat splenomegaly in cirrhotic patients. While splenectomy is an effective treatment of splenomegaly in the setting of cirrhosis, it is not without risk[4].Major complications include portal vein thrombosis and sepsis[4,5].Additionally, some cirrhotic patients may be poor surgical candidates, thus necessitating alternative approaches to splenomegaly amongst some cirrhotic patients. In 1973, Maddison performed the first splenic artery embolization. A farmer with non-alcoholic cirrhosis presented with intractable esophageal variceal bleeding which was resistant to treatment with intra-splenic arterial infusion of vasopressin. In the setting of significant prior bleeding surgical intervention was contraindicated, and Maddison performed an intra-arterial embolization of the splenic artery utilizing autologous clot as the embolic agent. The patient responded well and no complications were reported at 5 months follow-up[6].

Despite Maddison’s early success, numerous complications of total splenic artery embolization were soon discovered[7]. Complications included splenic abscess, splenic rupture, pneumonia, septicemia, and death. In response to these complications, Spigos transitioned to partial splenic embolization (PSE) paired with antibiotic prophylaxis and demonstrated significantly better outcomes[8]. Soon partial splenic embolization gained popularity and served as a therapeutic option for cirrhotic patients with hypersplenism who were poor surgical candidates.

Amin published a 2009 prospective randomized trial of 40 cirrhotic patients who presented with hypersplenism, treating half with PSE and half with splenectomy. Over the six-month follow-up period cohorts receiving splenectomy and PSE both demonstrated a significant increase in their leukocyte and platelet counts. Patients treated with PSE had slowly decreasing leukocyte and platelet levels during the follow-up period, though they remained significantly above pre-PSE levels. Of the 20 patients treated with PSE one died of myocardial infarction within one day postop, one developed splenic abscess, and one developed a portal vein thrombus. Of the 20 patients treated with splenectomy, three patients developed portal vein thrombosis. The surgical cohort had longer procedure times, longer hospitalizations, required transfusions more frequently, and reported more post-procedural pain[9].

**CLINICAL APPLICATIONS AND OUTCOMES OF PSE**

In 2007 Koconis *et al*[10] published a review of partial splenic artery embolization in patients with portal hypertension, thoroughly summarizing the English language literature and addressing numerous utilizations of PSE. Benefits included increased hepatic protein synthesis, increased circulating platelet and leukocyte levels, and improvements in hepatic encephalopathy.The most contemporary study noted in the Koconis *et al*[10] review was published in 2005. We performed a review of the English language literature for PSE and focused on papers from 2005 through the present. Ultimately, eight studies were identified, and have been included in our review (Table 1)[9,11-17]. In 2012, Smith *et al*[18] also published an excellent review of splenic artery embolization, which followed a similar structure.

***Hematologic indices***

One of the primary goals of PSE is to increase circulating platelets and leukocytes. Resultantly, serum platelet and leukocyte counts are a natural choice for measuring procedural effectiveness. Prior to exploration of the data it should be noted that Zhu *et al*[14]reported trends in laboratory values following PSE via a line graph without citing specific values. Consequently, reported values from Zhu *et al*[14]represent approximations. Assessment of leukocyte and platelet values following PSE demonstrates a few trends (Table 1). First, within two weeks of PSE both platelet and white blood cell values significantly increase. This was found to be consistent in all included studies. Pre-PSE platelet values ranged from 37.4-56 K/µL, and at two weeks following PSE platelet values ranged from 80-240.7 K/µL. Leukocytes also increased, with pre-PSE values ranging 2.3-4.2 K/µL and then jumping to 4.0-12.6 K/µL at two weeks. A second trend, which was uniform across every study and cohort, is the consistent decline in both leukocyte and platelet values in the months and years following PSE. Though the rate of decline varied from study to study, the presence of a decline is consistent. Finally, there is a direct relationship between the percent of spleen which is targeted via PSE and the magnitude of the response of circulating platelets and leukocytes. By dividing their study into cohorts based upon the percent of spleen targeted, the 2009 Zhu *et al*[14]study further demonstrated this point. Simply put, the larger the volume of targeted spleen, the greater the resultant increase in circulating leukocytes and platelets.

PSE’s ability to increase platelet and leukocyte counts has produced other clinical applications. Pegylated interferon and ribavirin induces sustained virological response in 42%-82% of patients with hepatitis C, however, thrombocytopenia is an absolute contraindication to the administration of therapy[19]. Over the past decade the use of PSE to increase platelet counts has facilitated antiviral treatment in patients who would have otherwise been too thrombocytopenic. Tahara completed a retrospective cohort study of 30 hepatitis C patients who were unable receive antiviral therapy secondary to thrombocytopenia and consequently were treated with PSE[20]. All 30 patients were able to receive therapy with pegylated interferon and ribavirin following a PSE-related increase in their platelet counts. A handful of other studies have demonstrated similar findings over the past decade[21-23].

Similar to the use of PSE to improve platelet counts prior to antiviral therapy in patients with hepatitis C, PSE has been used to increase hematologic indices to facilitate treatment of hepatocellular carcinoma. Hidaka *et al*[24] reported a 20 subject trial in which patients with multiple hepatocellular carcinoma lesions measuring less than 3 cm and platelet counts less than 80 received PSE to facilitate further treatment with radiofrequency ablation. Of the 20 patients, 18 demonstrated significant increases in prothombin function as well as platelet counts, and ultimately were treated with radiofrequency ablation. A smaller study demonstrated PSE to be an effective preoperative therapy to increase platelet counts prior to hepatectomy[25]. 5 patients received PSE prior to hepatectomy, while 23 patients received concomitant splenectomy with hepatectomy. The patients in the PSE arm received fewer blood transfusions and experienced fewer postoperative complications. Survival rates between the two arms were not significantly different.

***Portal hypertension and associated sequelae***

PSE has been demonstrated to improve portal hemodynamics in cirrhotic patients. PSE decreases splenic blood flow, splenic venous pressure, and portal venous pressure[26-28]. Additionally, in a trial of 7 patients with cirrhosis and hepatocellular carcinoma treated with a combination of transcatheter hepatic arterial embolization and PSE, Han demonstrated a significant decrease in portal venous pressures following therapy[29]. Interestingly, however, most studies which explored the hemodynamic effects of PSE did not demonstrate improvements in portal blood volume[26-28].

Portal venous hypertension is associated with numerous clinical manifestations. By improving portal hemodynamics, associated improvements in the sequelae of portal hypertension can be seen. Portal venous hypertension can lead to refractory ascites, and PSE has been found to decrease the incidence and magnitude of ascites[11]. Esophageal varices are also a common complication in patients with cirrhosis. Increased splenic arterial flow, splenic congestion, and portal venous pressures are all associated with an increased rupture risk of esophageal varices amongst cirrhotic patients[30,31]. By improving portal hemodynamics, PSE is associated with a decreased risk of variceal bleeding. Citing 4 studies, which included a total of 50 patients, Koconis *et al*[10] asserted that PSE decreased the annual incidence of variceal hemorrhage by 80%. Pälsson performed PSE in 26 patients with history of bleeding esophageal varices and thrombocytopenia, 19 of whom had cirrhosis. The cohort demonstrated a decrease in the number of variceal bleeding episodes from 4.3 prior to treatment to 1.1 after PSE[32]. Ohmoto conducted a study of 84 cirrhotic patients with large esophageal varices and thrombocytopenia[33]. 42 patients were treated with endoscopic variceal ligation (EVL) and 42 were treated with EVL and PSE. The combination therapy cohort demonstrated a reduced development of new varices from 88% to 67% (*p =* 0.038), decreased episodes of variceal bleeding from 34% to 17% (*p =* 0.024), and improved overall survival from 31% to 50% (*p =* 0.042). The literature also contains a case report of PSE being utilized to effectively address a 45-day decrease in hemoglobin secondary to diffuse gastric bleeding in portal hypertensive gastropathy[34].

PSE-related alterations in portal blood flow have also been shown to improve hepatic function[35]. Increased thrombopoietin, albumin, and cholinesterase levels as well as decreased alanine aminotransferase levels and total bilirubin levels have been demonstrated in cirrhotic patients following PSE[35,36]. These changes, however, are not uniform amongst all cirrhotic patients. Improved liver function following PSE is most pronounced in patients with initial splenic volumes greater than 600 cc[36]. In patients with hepatocellular carcinoma, PSE has been combined with transcatheter arterial chemoembolization (TACE) for promising results. In a comparison of patients treated with TACE and concomitant PSE versus TACE alone, those in the combined treatment cohort demonstrated improvements in platelet counts and hepatic reserve[37].

***Splenic artery steal syndrome***

Following liver transplant, approximately 5% of patients experience splenic artery steal syndrome (SASS). SASS is siphoning of arterial flow away from a transplanted liver due to a dominant splenic artery. While the hemodynamics of SASS are not completely understood, it is thought that increased resistance of the hepatic arterial bed and decreased resistance of the splenic arterial bed contribute to SASS[38]. High resistance of the hepatic arteries following liver transplant may be attributed to many causes, including a poorly compliant graft, post-operative edema, and subcapsular hematoma. Increased hepatic arterial resistance, when combined with low splenic arterial resistance due to splenomegaly, significantly increases splenic arterial flow while reflexively decreasing hepatic flow. Management of SASS may be surgical or endovascular. Surgical approaches include formation of an aortohepatic conduit or splenic arterial banding or ligation[38]. Proximal splenic artery embolization, via deployment of coils or an Amplatzer plug in the splenic artery immediately distal to the pancreatic and short gastric arteries, has been established as a safe and effective option in the non-surgical management of SASS[39-42].

**COMPLICATIONS OF PSE**

In exploring the morbidity and mortality associated with PSE, Koconis *et al*[10] reviewed 33 studies published between 1990 and 2005, and collectively representing 401 patients. In total, 15 major complications and 4 deaths were reported, for a major complication rate of 3.7% and a mortality rate of 1%. The rate of PSE-related complications consistently increased with volumes of splenic embolization near or greater than 70%[10].

PSE is not without risk, and the studies included in our review re-demonstrated many of the complications associated with the procedure (Table 2). Collectively, the studies we included demonstrate a direct relationship between the volume of spleen targeted for embolization and the severity of post-procedural complications. The 2009 Zhu *et al*[14] study further illustrated this point by subdividing patients in their study by percent of spleen targeted. The cohort receiving the greatest embolization (> 70%) also demonstrated the largest burden of complications. On the other hand, the patients with the least extensive embolization (< 50%) had the shortest hospital stays, lowest rate of embolization syndrome, and experienced no serious complications. Though not explicitly subdivided into cohorts based upon percent of spleen targeted during embolization, the 2008 Zhu *et al*[16] study also demonstrated an increased rate of complications among patients with embolization of > 70% of splenic volume.This correlates with the literature which has identified Child-Pugh class C and large splenic infarct volume as independent risk factors for complications with PSE[43]. Of the papers we included, Kim *et al*[11]had the smallest sample size, 11, and was an outlier in regards to their reported complications. Kim *et al*[11]reported 100% of their patients experienced post-embolization syndrome, but also reported zero serious complications. This was particularly surprising in that Kim *et al* targeted 70%-80% of the spleen for embolization, more than any other study.

**WORK-UP**

Workup of a patient prior to PSE includes a thorough history and physical, routine laboratory studies, imaging, and prophylactic antibiotics and vaccinations. A basic laboratory panel including a CBC, PT/PTT, liver function tests, renal function tests, and a hepatitis panel is commonly noted[12,44,45]. While less frequently mentioned, anti-platelet antibody studies and bone marrow biopsies have also been described[8,37]. Abdominal CT and ultrasound are useful to establish a splenic volume baseline and to screen for portal or splenic vein thrombosis[9,12-14,44-46]. Additionally, many authors endorse an upper gastrointestinal endoscopy in the workup prior to PSE to screen and/or treat esophageal varices[9,44,45]. Some authors, though not all, endorse the administration of pre-procedural broad spectrum antibiotics and/or vaccines. While Pneumovax 23 is the most commonly cited vaccination, the literature also makes note of H. influenza B and meningococcal vaccinations[18,46]. At our institution, broad-spectrum antibiotics are initiated just prior to PSE, and are continued for one to two weeks; additional vaccinations are not used.

**TECHNIQUE**

Numerous articles have described the technique of PSE, and generally concur in their description[9,12,46]. Vascular access is gained with a 5 French sheath in the femoral artery *via* the Seldinger technique. A 4 or 5 French cobra-type catheter is then utilized to isolate the celiac axis and splenic artery. Celiac and splenic angiography is performed to identify the distribution of splenic arteries, as well as document the presence of any collateral flow.

After mapping the anatomy of the celiac axis and the splenic artery, the catheter is secured at the site of embolization. Either a proximal or distal embolization may be performed. In the proximal, nonselective, approach the catheter is placed immediately distal to the origins of the pancreatic and short gastric arteries, and an embolic agent is released. Embolic agents are dispersed throughout the spleen and small, diffuse, randomized infarcts occur. In the distal, selective, approach, the catheter is advanced into a distal segmental branch of the splenic artery. The entire distal splenic segment is then embolized. Some authors believe sub-selection of the superior spleen is more likely to be associated with post procedural pneumonia and atelectasis, and therefore favor embolizing the inferior spleen; however, comparative studies have not been performed[18]. A microcatheter is preferred to secure access in the distal splenic segmental arteries. Of the contemporary studies reviewed for this paper, seven noted whether a distal or proximal approach was utilized. Six of the seven studies utilized a distal approach[12-15,44,47]. Though no randomized studies comparing distal and proximal PSE in cirrhotic patients have been completed, the majority of interventionalists report employing the distal approach. It should be noted, however, that the selection of a distal versus proximal approach may depend on the specific clinical scenario. Proximal embolization requires less time to accomplish and can be performed without use of microcatheter techniques. On the other hand sub-selecting distal splenic branches for embolization requires more time, but allows for greater precision in the percentage of splenic parenchyma that is targeted for embolization.

After identifying and securing the targeted vascular supply, embolization is performed. A variety of substances have been employed as embolic agents. Early descriptions of PSE mention the use of autologous clot. More contemporary approaches include gelatin sponge, polyvinyl alcohol particles (PVA), and tris-acryl gelatin microspheres. All of the above agents are typically delivered via a suspension containing contrast and, frequently, antibiotics. Of the studies reviewed, 14 noted the material used in embolization[9,12-15-18,33,44-48]. 8 of 14 used gel foam, 2 used tris-acryl gelatin microspheres, 2 used PVA particles, 1 used gelfoam and PVA particles in separate cohorts, and 1 used a combination of tris-acryl gelatin microspheres and PVA. Of the studies which reported use of tris-acryl gelatin microspheres, one study reported using 500-700 µm microspheres, another reported using 300-500 µm microspheres, and the final study noted using microspheres ranging 200-1000 µm[13,14,47]. In 2008 Zhu *et al*[16] published a study comparing the results of gelfoam embolization with PVA. Ultimately, the study demonstrated a slightly greater increase in platelet and leukocyte counts with PVA as compared to gelfoam. The study, however, also demonstrated greater frequency and magnitude of post-embolization syndrome amongst patients embolized with PVA as compared to gelfoam. At this time, no specific agent has clearly been established as a superior embolic agent in PSE.

Although coils and Amplatzer plugs are more commonly used to perform proximal splenic artery embolization (SAE) in the setting of trauma, recently, a small number of studies have highlighted the effectiveness of proximal SAE among patients with portal hypertension. Though only reporting use in six patients, Quintini *et al*[49] demonstrated coil-induced proximal SAE to be a safe and effective treatment for refractory ascites in patients with previous orthotopic liver transplants. Additionally, Zhu *et al*[50] performed a retrospective review of Amplatzer plugs versus coiling in SAE. While the majority of the patients included in the study received SAE secondary to splenic artery steal syndrome, one eighth of the subjects were included secondary to portal hypertension.

Some authors set their initial target at embolization of 50%-70% of the splenic blood volume. Others, however, embrace a more conservative approach and will target 30%-40% of the spleen with the expectations of repeating the embolization with a higher target area (up to 70%) if clinical symptoms do not respond to initial treatment. In an attempt to avoid embolization of a greater portion of the spleen many authors report an iterative process of delivering small aliquots of embolic material, and following each aliquot with an angiogram to determine the extent of embolization. The increased number of iterations allows providers to more precisely target a specific percent of splenic tissue, without excessively embolizing the spleen.

**POST PSE CARE**

The vast majority of patients experience some degree of pain, fever, and nausea/vomiting following PSE. These symptoms are collectively described as post-embolization syndrome[44]. Our review of the recent literature found that post-embolization syndrome is reported in 78.1%-100% of patients undergoing PSE (Tables 1 and 2). Patients are frequently hospitalized to receive supportive care for 24-48 h or until the post-embolization syndrome has resolved. Care is centered on antibiotic prophylaxis and pain management. Many antibiotics including amoxicillin/clavulanate, ofloxacin, phenoxymethylpenacillin, cotrimoxazole, cefoperazone, and erythromycin have been described in the literature. Post-procedural analgesia typically involves a combination of NSAIDS, scheduled morphine, and patient controlled analgesia (PCA).

Occasionally, patients experience more serious complications (Table 2). Severe complications are reported in 0%-34.8% of patients following PSE. The most common severe complication is pleural effusion and/or ascites, and can be treated with thoracentesis or paracentesis respectively. Other common morbidities include portal vein thrombosis and splenic abscess. Most practitioners advocate the use of anticoagulation in the treatment of post-PSE portal vein thrombosis, though Zhu *et al*[50]reported resolution of thrombus with watchful waiting. Presentation of splenic abscess has been reported between 10 d to 3 mo following PSE. Additionally, the majority of PSE-related deaths involve the development of a splenic abscess. Consequently, if post-procedural fever or other signs of infection develop, the threshold for ordering follow up imaging, usually with CT, should be low. Furthermore, due to the risks of splenic abscess, and the extended window in which it may develop, all PSE patients should be educated on the signs and symptoms of splenic abscess prior to the procedure and again upon discharge. Treatment of post-PSE splenic abscess includes percutaneous drainage and antibiotics, or occasionally, splenectomy. Mortality rates range from 0%-6.3% of patients undergoing PSE.

Follow up abdominal CT scan is frequently utilized in the first several weeks after PSE to confirm the percentage of infarcted splenic tissue. In the months following PSE, the spleen gradually decreases in size, but patients are usually followed clinically rather than monitoring with imaging, unless a complication is suspected.

**CONCLUSION**

PSE is an effective procedure in cirrhotic patients. It decreases rates of ascites and esophageal variceal bleeding while increasing hematologic indices. PSE can be an effective option for patients who are not surgical candidates and for whom splenectomy is contraindicated. In such patients, PSE may provide the necessary increase in hematologic indices to facilitate other treatments.

Still, PSE is not without its shortcomings. There are numerous morbidities associated with PSE. At the very least, almost all patients will experience post-embolization syndrome and will require post-procedural hospitalization. Several studies demonstrate major complication rates up to 15%-30% following PSE. The studies included in our review represented 260 patients, and collectively experienced a serious complication rate of 20.0% following PSE. In our study we included pleural effusions and ascites as major complications, and these accounted for 19 of the 52 complications. If we were to not include pleural effusions and ascites as major complications the average complication rate would have been 12.7%. Additionally, PSE-related mortality is consistently reported in 0%-6% of patients. The 260 patients included in our review collectively averaged a 2.3% mortality rate. In efforts to minimize PSE-related complications, targeted splenic volume for PSE ought to be below 70%. While an improvement of leukocyte and platelet counts has proven persistent, the magnitude of the increase consistently declines in the months and years following PSE.

Although PSE may not be appropriate in all cirrhotic patients, in the appropriate clinical context it is an efficacious tool which may provide clinical benefit for patients who otherwise may not be candidates for other medical and surgical interventions.

**References**

1 **Orlando R**, Lirussi F, Basso SM, Lumachi F. Splenomegaly as risk factor of liver cirrhosis. A retrospective cohort study of 2,525 patients who underwent laparoscopy. *In Vivo* 2011; **25**: 1009-1012 [PMID: 22021698]

2 **Bashour FN**, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. *Am J Gastroenterol* 2000; **95**: 2936-2939 [PMID: 11051371 DOI: 10.1111/j.1572-0241.2000.02325.x]

3 **Qamar AA**, Grace ND. Abnormal hematological indices in cirrhosis. *Can J Gastroenterol* 2009; **23**: 441-445 [PMID: 19543577]

4 **Ogata T**, Okuda K, Sato T, Hirakawa Y, Yasunaga M, Horiuchi H, Nomura Y, Kage M, Ide T, Kuromatsu R, Kinoshita H, Tanaka H. Long-term outcome of splenectomy in advanced cirrhotic patients with hepatocellular carcinoma and thrombocytopenia. *Kurume Med J* 2013; Epub ahead of print [PMID: 24064764 DOI: 10.2739/kurumemedj.MS62010]

5 **McCormick PA**, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. *Baillieres Best Pract Res Clin Gastroenterol* 2000; **14**: 1009-1031 [PMID: 11139352 DOI: 10.1053/bega.2000.0144]

6 **Maddison FE**. Embolic therapy of hypersplenism. *Invest Radiol* 1973; **8**: 280-281 [DOI: 10.1097/00004424-197307000-00054]

7 **Castaneda-Zuniga WR**, Hammerschmidt DE, Sanchez R, Amplatz K. Nonsurgical splenectomy. *AJR Am J Roentgenol* 1977; **129**: 805-811 [PMID: 410243 DOI: 10.2214/ajr.129.5.805]

8 **Spigos DG**, Jonasson O, Mozes M, Capek V. Partial splenic embolization in the treatment of hypersplenism. *AJR Am J Roentgenol* 1979; **132**: 777-782 [PMID: 107745 DOI: 10.2214/ajr.132.5.777]

9 **Amin MA**, el-Gendy MM, Dawoud IE, Shoma A, Negm AM, Amer TA. Partial splenic embolization versus splenectomy for the management of hypersplenism in cirrhotic patients. *World J Surg* 2009; **33**: 1702-1710 [PMID: 19513783 DOI: 10.1007/s00268-009-0095-2]

10 **Koconis KG**, Singh H, Soares G. Partial splenic embolization in the treatment of patients with portal hypertension: a review of the english language literature. *J Vasc Interv Radiol* 2007; **18**: 463-481 [PMID: 17446537 DOI: 10.1016/j.jvir.2006.12.734]

11 **Kim H**, Suh KS, Jeon YM, Park MS, Choi Y, Mori S, Hong G, Lee HW, Yi NJ, Lee KW. Partial splenic artery embolization for thrombocytopenia and uncontrolled massive ascites after liver transplantation. *Transplant Proc* 2012; **44**: 755-756 [PMID: 22483487 DOI: 10.1016/j.transproceed.2012.01.066]

12 **Elmonem SA**, Tantawy HI, Ragheb AS, Matar NEH, Tantawi I. The outcome of partial splenic embolization for hypersplenism in cirrhotic patients. *Egypt J Radiol Nuc Med* 2011; **42**: 35-42 [DOI: 10.1016/j.ejrnm.2011.01.002]

13 **N'Kontchou G**, Seror O, Bourcier V, Mohand D, Ajavon Y, Castera L, Grando-Lemaire V, Ganne-Carrie N, Sellier N, Trinchet JC, Beaugrand M. Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients. *Eur J Gastroenterol Hepatol* 2005; **17**: 179-184 [PMID: 15674095 DOI: 10.1097/00042737-200502000-00008]

14 **Zhu K**, Meng X, Qian J, Huang M, Li Z, Guan S, Jiang Z, Shan H. Partial splenic embolization for hypersplenism in cirrhosis: a long-term outcome in 62 patients. *Dig Liver Dis* 2009; **41**: 411-416 [PMID: 19070555 DOI: 10.1016/j.dld.2008.10.005]

15 **Lee CM**, Leung TK, Wang HJ, Lee WH, Shen LK, Liu JD, Chang CC, Chen YY. Evaluation of the effect of partial splenic embolization on platelet values for liver cirrhosis patients with thrombocytopenia. *World J Gastroenterol* 2007; **13**: 619-622 [PMID: 17278231]

16 **Zhu K**, Meng X, Li Z, Huang M, Guan S, Jiang Z, Shan H. Partial splenic embolization using polyvinyl alcohol particles for hypersplenism in cirrhosis: a prospective randomized study. *Eur J Radiol* 2008; **66**: 100-106 [PMID: 17532166 DOI: 10.1016/j.ejrad.2007.04.010]

17 **Hayashi H**, Beppu T, Masuda T, Mizumoto T, Takahashi M, Ishiko T, Takamori H, Kanemitsu K, Hirota M, Baba H. Predictive factors for platelet increase after partial splenic embolization in liver cirrhosis patients. *J Gastroenterol Hepatol* 2007; **22**: 1638-1642 [PMID: 17683504 DOI: 10.1111/j.1440-1746.2007.05090.x]

18 **Smith M**, Ray CE. Splenic artery embolization as an adjunctive procedure for portal hypertension. *Semin Intervent Radiol* 2012; **29**: 135-139 [PMID: 23729984 DOI: 10.1055/s-0032-1312575]

19 **Sato K**, Takagi H, Ichikawa T, Kakizaki S, Mori M. Emerging therapeutic strategies for hepatitis C virus infection. *Curr Mol Pharmacol* 2008; **1**: 130-150 [PMID: 20021428 DOI: 10.2174/1874467210801020130]

20 **Tahara H**, Takagi H, Sato K, Shimada Y, Tojima H, Hirokawa T, Ohyama T, Horiuchi K, Naganuma A, Arai H, Kakizaki S, Mori M. A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia. *J Gastroenterol* 2011; **46**: 1010-1019 [PMID: 21594564 DOI: 10.1007/s00535-011-0407-9]

21 **Takahara M**, Miyake Y, Miyatake H, Imagawa A, Nakatsu M, Ando M, Hirohata M, Yamamoto K. Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia. *Intern Med* 2011; **50**: 2731-2736 [PMID: 22082883 DOI: 10.2169/internalmedicine.50.6143]

22 **Miyake Y**, Ando M, Kaji E, Toyokawa T, Nakatsu M, Hirohata M. Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia. *Hepatol Res* 2008; **38**: 980-986 [PMID: 18657124 DOI: 10.1111/j.1872-034X.2008.00357.x]

23 **Foruny JR**, Blázquez J, Moreno A, Bárcena R, Gil-Grande L, Quereda C, Pérez-Elías MJ, Moreno J, Sánchez J, Muriel A, Rodriguez-Sagrado MA, Moreno S. Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. *Eur J Gastroenterol Hepatol* 2005; **17**: 1157-1164 [PMID: 16215426 DOI: 10.1097/00042737-200511000-00002]

24 **Hidaka H**, Kokubu S, Nakazawa T, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Shibuya A, Saigenji K. Therapeutic benefits of partial splenic embolization for thrombocytopenia in hepatocellular carcinoma patients treated with radiofrequency ablation. *Hepatol Res* 2009; **39**: 772-778 [PMID: 19473438 DOI: 10.1111/j.1872-034X.2009.00508.x]

25 **Yoshidome H**, Kimura F, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, Furukawa K, Takeuchi D, Takayashiki T, Suda K, Takano S, Miyazaki M. Usefulness of preoperative partial splenic embolization in hepatocellular carcinoma and hypersplenic thrombocytopenia. *Hepatogastroenterology* 2011; **58**: 2062-2066 [PMID: 22234078]

26 **Chikamori F**, Kuniyoshi N, Kawashima T, Takase Y. Short-term portal hemodynamic effects of partial splenic embolization for hypersplenism. *Hepatogastroenterology* 2007; **54**: 1847-1849 [PMID: 18019732]

27 **Yamashiro K**, Mukaiya M, Kumura H, Katsurmaki T, Sasaki K, Denno R, Hirata K. Partial splenic embolization in patients with liver cirrhosis and hepatocellular carcinoma: Effects on portal hemodynamics. *J Hep Bil Pancr Surg* 1994; **2**: 172-175 [DOI: 10.1007/BF01222244]

28 **Mukaiya M**, Hirata K, Yamashiro K, Katsuramaki T, Kimura H, Denno R. Changes in portal hemodynamics and hepatic function after partial splenic embolization (PSE) and percutaneous transhepatic obliteration (PTO). *Cancer Chemother Pharmacol* 1994; **33** Suppl: S37-S41 [PMID: 8137483 DOI: 10.1007/BF00686666]

29 **Han MJ**, Zhao HG, Ren K, Zhao DC, Xu K, Zhang XT. Partial splenic embolization for hypersplenism concomitant with or after arterial embolization of hepatocellular carcinoma in 30 patients. *Cardiovasc Intervent Radiol* 1997; **20**: 125-127 [PMID: 9030503 DOI: 10.1007/s002709900119]

30 **Kayacetin E**, Efe D, Doğan C. Portal and splenic hemodynamics in cirrhotic patients: relationship between esophageal variceal bleeding and the severity of hepatic failure. *J Gastroenterol* 2004; **39**: 661-667 [PMID: 15293137 DOI: 10.1007/s00535-003-1362-x]

31 **Garcia-Tsao G**, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. *Hepatology* 1985; **5**: 419-424 [PMID: 3873388 DOI: 10.1002/hep.1840050313]

32 **Pålsson B**, Hallén M, Forsberg AM, Alwmark A. Partial splenic embolization: long-term outcome. *Langenbecks Arch Surg* 2003; **387**: 421-426 [PMID: 12607123]

33 **Ohmoto K**, Yoshioka N, Tomiyama Y, Shibata N, Takesue M, Yoshida K, Kuboki M, Yamamoto S. Improved prognosis of cirrhosis patients with esophageal varices and thrombocytopenia treated by endoscopic variceal ligation plus partial splenic embolization. *Dig Dis Sci* 2006; **51**: 352-358 [PMID: 16534680 DOI: 10.1007/s10620-006-3137-8]

34 **Shimizu T**, Onda M, Tajiri T, Yoshida H, Mamada Y, Taniai N, Aramaki T, Kumazaki T. Bleeding portal-hypertensive gastropathy managed successfully by partial splenic embolization. *Hepatogastroenterology* 2002; **49**: 947-949 [PMID: 12143250]

35 **Hidaka H**, Kokubu S, Saigenji K, Isobe Y, Maeda T. Restoration of thrombopoietin production after partial splenic embolization leads to resolution of thrombocytopenia in liver cirrhosis. *Hepatol Res* 2002; **23**: 265 [PMID: 12191674 DOI: 10.1016/S1386-6346(02)00002-5]

36 **Hayashi H**, Beppu T, Masuda T, Okabe H, Imai K, Hashimoto D, Ikuta Y, Chikamoto A, Watanabe M, Baba H. Large splenic volume may be a useful predictor for partial splenic embolization-induced liver functional improvement in cirrhotic patients. *J Hepatobiliary Pancreat Sci* 2014; **21**: 51-57 [PMID: 23798315 DOI: 10.1002/jhbp.1]

37 **Ishikawa T**, Kubota T, Horigome R, Kimura N, Honda H, Iwanaga A, Seki K, Honma T, Yoshida T. Concurrent partial splenic embolization with transcatheter arterial chemoembolization for hepatocellular carcinoma can maintain hepatic functional reserve. *Hepatol Res* 2013; Epub ahead of print [PMID: 23941627 DOI: 10.1111/hepr.12222]

38 **Saad WE**. Nonocclusive hepatic artery hypoperfusion syndrome (splenic steal syndrome) in liver transplant recipients. *Semin Intervent Radiol* 2012; **29**: 140-146 [PMID: 23729985 DOI: 10.1055/s-0032-1312576]

39 **Chao CP**, Nguyen JH, Paz-Fumagalli R, Dougherty MK, Stockland AH. Splenic embolization in liver transplant recipients: early outcomes. *Transplant Proc* 2007; **39**: 3194-3198 [PMID: 18089351 DOI: 10.1016/j.transproceed.2007.07.089]

40 **Sevmis S**, Boyvat F, Aytekin C, Gorur SK, Karakayali H, Moray G, Haberal M. Arterial steal syndrome after orthotopic liver transplantation. *Transplant Proc* 2006; **38**: 3651-3655 [PMID: 17175358 DOI: 10.1016/j.transproceed.2006.10.145]

41 **Mogl MT**, Nüssler NC, Presser SJ, Podrabsky P, Denecke T, Grieser C, Neuhaus P, Guckelberger O. Evolving experience with prevention and treatment of splenic artery syndrome after orthotopic liver transplantation. *Transpl Int* 2010; **23**: 831-841 [PMID: 20180930 DOI: 10.1111/j.1432-2277.2010.01062.x]

42 **Maurer MH**, Mogl MT, Podrabsky P, Denecke T, Grieser C, Fröling V, Scheurig-Münkler C, Guckelberger O, Kroencke TJ. Splenic artery syndrome after orthotopic liver transplantation: treatment with the Amplatzer vascular plug. *Cardiovasc Intervent Radiol* 2011; **34**: 1208-1213 [PMID: 21184225 DOI: 10.1007/s00270-010-0083-9]

43 **Hayashi H**, Beppu T, Okabe K, Masuda T, Okabe H, Baba H. Risk factors for complications after partial splenic embolization for liver cirrhosis. *Br J Surg* 2008; **95**: 744-750 [PMID: 18412294 DOI: 10.1002/bjs.6081]

44 **Sakai T**, Shiraki K, Inoue H, Sugimoto K, Ohmori S, Murata K, Takase K, Nakano T. Complications of partial splenic embolization in cirrhotic patients. *Dig Dis Sci* 2002; **47**: 388-391 [PMID: 11855556 DOI: 10.1023/A: 1013786509418]

45 **Pandey R**, Garg R, Darlong V, Punj J, Kumar A. Role of splenic artery partial embolization in a patient with portal hypertension and pancytopenia undergoing hysterectomy under anesthesia. *AANA J* 2012; **80**: 96-98 [PMID: 22586877]

46 **Gowda NK**, D’Souza D, Golzarian J. Partial splenic artery embolization. *Endovascular Today* 2012; **11**: 74-76.

47 **Noguchi H**, Hirai K, Aoki Y, Sakata K, Tanikawa K. Changes in platelet kinetics after a partial splenic arterial embolization in cirrhotic patients with hypersplenism. *Hepatology* 1995; **22**: 1682-1688 [PMID: 7489974 DOI: 10.1002/hep.184022061]

48 **Sockrider CS**, Boykin KN, Green J, Marsala A, Mladenka M, McMillan R, Zibari GB. Partial splenic embolization for hypersplenism before and after liver transplantation. *Clin Transplant* 2002; **16** Suppl 7: 59-61 [PMID: 12372046 DOI: 10.1034/j.1399-0012.16.s7.9.x]

49 1 **Quintini C**, D'Amico G, Brown C, Aucejo F, Hashimoto K, Kelly DM, Eghtesad B, Sands M, Fung JJ, Miller CM. Splenic artery embolization for the treatment of refractory ascites after liver transplantation. *Liver Transpl* 2011; **17**: 668-673 [PMID: 21618687 DOI: 10.1002/lt.22280]

50 **Zhu X**, Tam MD, Pierce G, McLennan G, Sands MJ, Lieber MS, Wang W. Utility of the Amplatzer Vascular Plug in splenic artery embolization: a comparison study with conventional coil technique. *Cardiovasc Intervent Radiol* 2011; **34**: 522-531 [PMID: 20700592 DOI: 10.1007/s00270-010-9957-0]

**P-Reviewers:** Ferraioli G, Kiyosue H, Vogl TJ, Yuan Z **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

# Table 1 Study demographics and outcomes of partial splenic embolization

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Country** | **Study type** | **Number of Pts** | **Length of Follow-up** | **Mean ± SD, platelet count prior to PSE in K/µL** | **Mean ± SD, WBC count prior to PSE in K/µL** | **Indication for PSE** | **Extent of spleen targeted** | **Mean ± SD, platelet count at 2 wk in K/µL** | **Mean ± SD, platelet count at 1 mo in K/µL** | **Mean ± SD, platelet count at 1 yr in K/µL** | **Mean ± SD, WBC count at 2 wk in K/µL** | **Mean ± SD, WBC count at 1 mo in K/µL** | **Mean ± SD, WBC count at 1 yr in K/µL** |
|
|
|
| Kim *et al*[11] | 2012 | South Korea | Case series report | 11 | 6-28 mo | Not Provided | Not Provided | All patients S/P OLT; 6/11 w/ thrombocytopenia, 5/11 w/ refractory ascites | 70%-80% | Not provided | Not provided | Not provided | Not provided | Not provided | Not provided |
|
|
|
| Elmonem *et al*[12] | 2010 | Egypt | Case series report | 23 | 2 yr | 41.3 ± 13.0 | 2.3 ± 0.47 | Hypersplenism in Cirrhosis w/ leukopenia and thrombocytopenia, no HCC, and no SBP | 50%-70% | 124.3 ± 23.9 | 115.8 ± 18.4 | 94.1 ± 12.9 | 8.26 ± 1.54 | 6.53 ± 1.74 | 4.62 ± 1.13 |
|
|
|
| Zhu *et al*[14] | 2009 | China | Nonrandomized prospectivet trial | Total 62  Group A: 12  Group B: 34  Group C: 16 | 5 yr | Group A: 40.2 ± 13.0 Group B: 37.4 ± 12.3 Group C: 43.6 ± 11.7 | Group A: 2.42 ± 0.44 Group B: 2.54 ± 0.57 Group C: 2.64 ± 0.4 | Hypersplenism in Cirrhosis, w/ thrombocytopenia or neutropenia. No SBP, No Severe Jaundice | 50%-70% | Group A: 1701 Group B: 1301  Group C:801 | Group A: 1301 Group B: 1101 Group C: 701 | Group A: 1001 Group B: 901 Group C: 501 | Group A: 7.51 Group B: 6.51 Group C: 4.01 | Group A: 6.01 Group B: 5.51 Group C: 3.71 | Group A: 4.51 Group B: 4.01 Group C: 3.01 |
|
|
|
| Amin *et al*[9] | 2009 | Egypt | Randomized control trial | Total 40  PSE: 20  SPL: 20 | 6 mo | PSE: 39.7 ± 9.7 SPL: 47.2 ± 10.3 | PSE: 3.3 ± 0.7 SPL: 2.8 ± 1.1 | Cirrhosis w/o bone marrow disease, ischemic heart disease, renal failure, malignancy, or medical unstability | 50% | PSE:211.5 ± 36.2 SPL: 240.7 ± 52.0 | Not provided | Not provided | PSE： 12.6 ± 2.6 SPL： 7.7 ± 1.9 | Not provided | Not provided |
|
|
|
| Zhu *et al*[16] | 2008 | China | Randomized control trial | Total 60  GF: 32  PVA: 28 | 3 yr | GF: 47.06 ± 14.85 PVA: 44.36 ± 16.67 | GF: 2.62 ± 0.67 PVA: 2.57 ± 0.63 | Hypersplenism in cirrhosis w/ thrombocytopenia or neutropenia. No SBP, No HCC, No Hyperbilirubinemia | 50%-70% | GF: 135.4 ± 28.1 PVA: 153.4 ± 37.1 | GF: 113.2 ± 17.6 PVA: 125.4 ± 23.3 | GF: 95.8 ± 13.9 PVA: 106.2 ± 17.2 | GF： 6.6 ± 1.5 PVA： 7.5 ± 1.7 | GF： 5.1 ± 0.9 PVA： 5.7 ± 1.2 | GF： 4.2 ± 0.6 PVA： 4.7 ± 1.0 |
|
|
|
| Hayashi *et al*[17] | 2007 | Japan | Nonrandomized prospective trial | 42 | 1 yr | 45 ± 11.7 | 2.9 ± 1.0 | Thrombocytopenia caused by hypersplenism due to cirrhosis | 70%-80% | Not provided | 116 ± 51 | 103 ± 34 | Not provided | Not provided | Not provided |
|
|
|
| Lee *et al*[15] | 2007 | China | Nonrandomized prospective trial | 10 | 1 yr | 56 ± 8.0 | Not Provided | Thrombocytopenia in setting of cirrhosis | 20%-40% | 192.0 | Not provided | 145.0 | Not provided | Not provided | Not provided |
|
|
|
| N'Kontchou *et al*[13] | 2005 | France | Retrospective review | 32 | 1-87 mo | 48 ± 14 | 4.2 ± 1.6 | Cirrhosis w/ severe cytopenia/leukopenia preventing treatment or severe purpur, or painful splenomegally | 50% | Not provided | 137.5 ± 77.4 | Not provided | Not provided | 6.5 ± 2.9 | Not provided |
|
|
|

# 1Data From Zhu *et al* was extracted from a graph without exact values, values used are the authors closest approximations. PSE: Partial splenic artery embolization; SPL: Splenectomy; GF: Gel foam; PVA: Polyvinyl alcohol.

# Table 2 Complications in partial splenic artery embolization

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Country** | **Study Type** | **Complication: Frequency of post embolization syndrome** | **Complication: Mean length of post embolization syndrome - Days** | **Major complications: Total number** | **Persistant thrombocytopenia** | **Splenomegaly** | **Pleural effusion/ascites** | **Variceal bleeding** | **Portal vein thrombosis** | **Bacterial peritonitis** | **Splenic abscess** | **PSE-related death** | **Repeat embolization required** |
|
|
|
| Kim *et al*[11] | 2012 | South Korea | Case series report | 100.0% | Not provided | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
|
|
|
| Elmonem *et al*[12] | 2010 | Egypt | Case series report | 91.3% | Not provided | 34.8% | 4.3% | 4.3% | 8.7% | 0.0% | 4.3% | 4.3% | 4.3% | 4.3% | 4.3% |
|
|
|
| Zhu *et al*[14] | 2009 | China | Nonrandomized prospective trial | Total 85.5% Group A: 100% Group B: 91.2 % Group C: 62.5% | Group A: 13 Group B: 7 Group C: 3 | Total 14.5% Group A: 50% Group B: 8.8% Group C: 0% | Total 0% Group A: 0% Group B: 0% Group C: 0% | Total 0% Group A: 0% Group B: 0% Group C: 0% | Total 4.8% Group A: 16.6% Group B: 2.9% Group C: 0% | Total 1.6% Group A: 8.3% Group B: 0% Group C: 0% | Total 1.6% Group A: 8.3% Group B: 0% Group C: 0% | Total 1.6% Group A: 8.3% Group B: 2.9% Group C: 0% | Total 1.6% Group A: 8.3% Group B: 0% Group C: 0% | Total 1.6% Group A: 8.3% Group B: 0% Group C: 0% | Total 0% Group A: 0% Group B: 0% Group C: 0% |
|
|
|
| Amin *et al*[9] | 2009 | Egypt | Randomized control trial | Not provided | PSE: 2.1 (0.4) SPL: 4.3 (1.1) | PSE: 25% SPL: 25% | PSE: 0% SPL: 0% | PSE: 0% SPL： 0% | PSE: 10% SPL: 10% | PSE: 0% SPL: 0% | PSE: 5% SPL： 15% | PSE: 0% SPL: 0% | PSE: 5% SPL: 0% | PSE: 5% SPL: 0% | PSE： 0% SPL： 0% |
|
|
|
| Zhu *et al*[16] | 2008 | China | Randomized control trial | GF: 90.6% PVA: 100% | GF: 6.4 (3.6) PVA: 7.6 (2.8) | GF: 25.0% PVA: 21.4% | GF: 0% PVA: 0% | GF: 0% PVA: 0% | GF: 9.4% PVA: 10.7% | GF: 3.1% PVA: 3.6% | GF: 3.1% PVA: 7.1% | GF: 6.3% PVA: 0% | GF: 3.1% PVA: 0% | GF: 3.1% PVA: 0% | GF: 0% PVA： 0% |
|
|
|
| Hayashi *et al*[17] | 2007 | Japan | Nonrandomized prospective trial | 100.0% | Not provided | 11.9% | 0.0% | 0.0% | 9.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
|
|
|
| Lee *et al*[15] | 2007 | China | Nonrandomized prospective trial | 100.0% | Not provided | 10.0% | 0.0% | 0.0% | 10.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
|
|
|
| N'Kontchou *et al*[13] | 2005 | France | Retrospective review | 78.1% | 14.0 | 28.1% | 3.1% | 0.0% | 6.3% | 0.0% | 6.3% | 0.0% | 6.3% | 6.3%5 | 3.1% |
|
|
|

# Both deaths in the trial were in patients with > 70% splenic embolization. PSE: Partial splenic artery embolization; SPL: Splenectomy; GF: Gel foam; PVA: Polyvinyl alcohol.